(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202112 | 202012 | % Var | 202112 | 202012 | % Var | 202103 | 202003 | % Var | |
| Sales | 26230.50 | 37351.70 | -29.77 | 83999.80 | 117096.60 | -28.26 | 158236.80 | 133707.70 | 18.35 |
| Other Income | 1312.90 | 1583.20 | -17.07 | 2576.10 | 3224.50 | -20.11 | 5898.60 | 2434.30 | 142.31 |
| PBIDT | 3472.00 | 11341.20 | -69.39 | 12240.60 | 34662.70 | -64.69 | 47096.80 | 29412.90 | 60.12 |
| Interest | 35.40 | 58.60 | -39.59 | 120.40 | 227.50 | -47.08 | 286.80 | 979.10 | -70.71 |
| PBDT | 3436.60 | 11282.60 | -69.54 | 12120.20 | 34435.20 | -64.80 | 46810.00 | 28433.80 | 64.63 |
| Depreciation | 1012.00 | 1222.10 | -17.19 | 3140.30 | 3639.20 | -13.71 | 4879.90 | 4733.30 | 3.10 |
| PBT | 2424.60 | 10060.50 | -75.90 | 8979.90 | 30796.00 | -70.84 | 41930.10 | 23700.50 | 76.92 |
| TAX | 26.50 | 2701.40 | -99.02 | 2454.30 | 8392.30 | -70.76 | 10801.00 | 4931.70 | 119.01 |
| Deferred Tax | -861.60 | 17.50 | -5023.43 | -1088.60 | 48.70 | -2335.32 | 367.60 | 8.80 | 4077.27 |
| PAT | 2398.10 | 7359.10 | -67.41 | 6525.60 | 22403.70 | -70.87 | 31129.10 | 18768.80 | 65.86 |
| Equity | 585.90 | 585.90 | 0.00 | 585.90 | 585.90 | 0.00 | 585.90 | 585.90 | 0.00 |
| PBIDTM(%) | 13.24 | 30.36 | -56.41 | 14.57 | 29.60 | -50.77 | 29.76 | 22.00 | 35.30 |
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1904.65 |
| Dr. Reddys Labs. | 1374.55 |
| Cipla | 1458.45 |
| Zydus Lifesciences | 1141.00 |
| Lupin | 2476.10 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: